Current Edition

Biologic Medicines and Patient-centricity – A New Phase of Hope

The global pharmaceutical industry has entered an exciting new era of drug development, bringing new hope to patients around the world. It is estimated that close to 40 per cent of all medicines in pipeline development are biologic in nature. The world’s top-selling commercial biologic medicines cover a broad range of diseases. Justin Schroeder, PCI, explores how biologic medicines have transformed treatment and personal care for patients, as well as providing breakthrough therapies.